Close button
The Guardian
Email YouTube Facebook Instagram Twitter WhatsApp

Scientists claim third type of diabetes


Diabetes Test

*There is no safe amount of alcohol during pregnancy as drug reduces weight in obese
A new study claims that people are at risk for developing severe problems with their pancreas after being misdiagnosed with type 2 diabetes.

Type 3c diabetes occurs as a result of pancreatic inflammation, abnormal growth of tissue on the organ or surgically removing part or all of the tissue, which affects the body’s ability to produce insulin.

The study claims that people who previously had a pancreatic disease could have been misdiagnosed with type 2 diabetes, which can cause the wrong treatment plan.


Researchers said the United States National Health Service and health experts need to distinguish between the types of diabetes to avoid providing the wrong care to a patient.

Experts from the University of Surrey examined the patient medical records of more than two million Britons to assess the frequency of different types of diabetes and the accuracy of diagnosis.

The study, published in the journals Diabetes Care, found that up to 97.3 percent of people who have previously experienced pancreatic disease are misdiagnosed, typically with Type 2 diabetes.

Type 2 diabetes occurs when the body doesn’t produce enough insulin to function properly, or the body’s cells don’t react to insulin so the glucose stays in the blood instead of being used as fuel.

This is often associated with obesity in people middle-aged or older. In contrast, type 3c diabetes happens following damage to the pancreas. It is also termed ‘pancreatogenic diabetes’.

Someone might have this if they are experiencing symptoms of cystic fibrosis, inflammation in the pancreas or pancreatic cancer. A wrong diagnosis can impact the treatment offered to patients. Type 3c diabetes requires insulin therapy more urgently than type 2 diabetes to defect the glucose deficiency in the blood.

Also, according to new research from Binghamton University, State University of New York, United States, any amount of alcohol exposure during pregnancy can cause extreme lasting effects on a child.

A team of researchers led by Marvin Diaz, assistant professor of psychology at Binghamton University, determined that even a small to moderate amount of alcohol exposure produces significant amounts of anxiety in offspring, lasting through adolescence and into adulthood. This research differed in its use of only low levels of alcohol exposure, whereas prior studies used high levels of exposure to reach the same conclusion.

Also, according to new research, a drug that targets the appetite control system in the brain could bring about significant weight loss in people with clinical obesity.

On average, people lost 5kg (11lbs) over a 12 week period after receiving weekly doses of semaglutide, a compound currently being developed as a treatment for Diabetes.

Most of the weight loss came from a reduction in body fat, researchers at the University of Leeds found after reviewing its effectiveness. The drug reduced food cravings, with people choosing to eat smaller meals and decreasing their preferences for foods with a higher fat content.

The study also added to the scientific understanding of how drug therapy can be used to tackle obesity. For the first time, scientists saw the benefit of very specific targeting of receptors or sensors that could affect multiple components of the brain’s appetite control system.


The research has been published in the journal Diabetes, Obesity and Metabolism.

Semaglutide is a new drug being developed by the Danish pharmaceutical company Novo Nordisk as a treatment for diabetes.

Its chemical structure is very similar to the naturally occurring hormone GLP-1 that is believed to act on the appetite control centre in the hypothalamus in the brain to reduce feelings of hunger.

Given the close similarity between semaglutide and the body’s own appetite-control chemical, the study set out to examine whether the drug could also be used to tackle obesity by acting on the brain’s appetite control receptors.


In this article:
Receive News Alerts on Whatsapp: +2348136370421

No comments yet